Image
 

Locate Available Clinical Trials

To view available Clinical Trial information choose from the list on the right or search using the fields below.

 

 

trial #
trial description
  • Alliance A011104
  • The purpose of this study is to test whether patients undergoing a breast MRI (called magnetic resonance imaging) before breast cancer surgery will have better results after the surgery.

  • Alliance A011106
  • The purpose of this study is to determine whether neoadjuvant endocrine therapy with fulvestrant or the combination of anastrozole and fulvestrant, is better than anastrozole when given before surgery for breast cancer to shrink the cancer and stop it from growing. 

  • Alliance A011202
  • The purpose of this study is to examine whether removing some of the lymph nodes from the arm pit during breast cancer surgery, but not removing them all followed with radiation therapy (research portion of the study) will be as good as having the majority of the lymph nodes from the arm pit removed during breast surgery followed with radiation (standard of care portion of the study).

  • Alliance A011401
  •  This study is being done to see if losing weight may help prevent breast cancer from coming back (recurring). Previous studies have found that women who are overweight or obese when their breast cancer is found (diagnosed) have a greater risk of their breast cancer recurring, as compared to women who were thinner when their cancer was diagnosed. At this time we do not know whether or not losing weight will reduce the risk of breast cancer returning.  This study seeks to determine whether or not the higher risk for breast cancer recurrence in women who are overweight or obese when they are diagnosed with breast cancer could be reduced or eliminated if weight is lost. This study will help to show us whether weight loss programs should be a part of breast cancer treatment.

  • Alliance A011502
  • The purpose of this study is to compare any good and bad effects of using aspirin after someone has completed the usual chemotherapy, surgery and/or radiation therapy for breast cancer. Some studies have suggested that aspirin may lower the risk of breast cancer coming back, but others have not, so we do not know if aspirin will help decrease breast cancer recurrence. This study will evaluate whether patients taking aspirin once per day will have a lower rate of cancer recurrence than patients taking a placebo. A placebo is a tablet that looks like the study drug (aspirin), but contains no medication. 

  • Alliance A211102
  • The purpose of this research study is to test whether metformin, a drug commonly used to treat diabetes, is able to get rid of atypia (or marker of breast cancer risk) in women at increased risk for breast cancer.  We will test for the presence of atypia in the breast after metformin is given to see if it can get rid of atypia. We would like to compare the effects, good and/or bad, of metformin or placebo on atypia to find out which is better.  In this study, you will get either metformin or a placebo (an inactive product) for the first twelve months.  After the first twelve months, women who received placebo during the first twelve months can choose to receive metformin for the second year.

  • Alliance A211201
  • This study is being done as a related study to the MA.32 clinical trial (also called a “companion study”), to see if the use of metformin causes a decrease in mammographic breast density.The breast is composed of fat, milk glands, and various other tissues, which determine how dense the breasts are. High breast density has been shown to be a strong risk factor for developing breast cancer. It is thought that decreasing breast density may decrease the risk for breast cancer. The main goal of this study is to see whether women treated with metformin will have reduced breast density as seen on a mammogram.

  • Alliance A221102
  • The purpose of this study is to compare the effects, good and/or bad, of the study drug, testosterone, with a placebo (an inactive drug) on joint pain caused by taking aromatase inhibitors for treatment of breast cancer.  The testosterone will be mixed with a little anastrozole to prevent any medication from turning into estrogen. The testosterone/placebo is a pellet that is placed just under your skin on the upper buttocks or lower abdomen.  In this study, you will receive either the testosterone or placebo.  You will not receive both. 

  • Alliance A221405
  • The purpose of this study is to determine whether having a child after temporarily stopping endocrine treatment is feasible and safe in patients with a hormone receptor-positive early breast cancer. Specifically, the study will investigate whether a temporary interruption of endocrine therapy, with the goal of permitting pregnancy and then resuming endocrine therapy to complete a standard course, is associated with a higher risk of breast cancer recurrence. In addition, the study aims to evaluate the success of pregnancy, the health of the newborn, and the patient’s ability to breastfeed.

  • CTSU E1Z11
  • This research is being done to find out what effects, good and/or bad, that anastrozole has on you and whether your genes can help explain how anastrozole affects you. 

  • CTSU E2112
  • The purpose of this study is find out what effects, both good and bad, a research drug called entinostat has on you and your cancer, when given together with the standard hormonal drug treatment, exemestane.

  • CTSU EA1131
  • The main purpose of this study is to compare the usual approach  to your type of breast cancer (i.e. no more treatment), to any good and bad effects of getting more treatment with a platinum-based chemotherapy (cisplatin or carboplatin), after surgery.

  • CTSU EAI142
  • The purpose of this research study is to test if an imaging drug, not approved by the Food and Drug Administration (FDA), called FES, is useful for evaluating your metastatic breast cancer and predicting how well your cancer responds to therapy. This drug is used with a PET/CT scan. The researchers want to see if the PET/CT scan, using the study drug, can improve upon the usual way of choosing treatment for your type of cancer. 

  • CTSU ECOG-ACRIN EA1141
  • NRG BR001
  • This study is for patients who have received treatment to the breast, lung or prostate (the first location of cancer) and now the cancer has spread to other parts of the body that have not yet been treated. The purpose of this study is to test the safety of giving a few, focused, high doses of radiation (commonly referred to as stereotactic body radiotherapy [SBRT]) to all known sites of cancer within your body.  

  • NRG BR002
  • The purpose of this study is to compare any good or bad effects of delivering ablative local therapy to all known metastatic tumor sites, (even those that are not causing symptoms); in addition to the usual approach of intravenous or oral medications for treatment of breast cancer that has spread to 1 or 2 body sites.  Ablative means that the intention of the local treatment is to put an end to the cancer at that metastatic site. The ablative local therapy can be either very focused, intensive radiotherapy called Stereotactic Body Radiotherapy (SBRT) or surgical resection. Both SBRT and surgical resection have been tested for safety, but are not part of the usual approach.                   

  • NRG BR003
  • The purpose of this study is to compare the good and bad effects of the chemotherapy drug, carboplatin, given with the usual chemotherapy drugs after surgery, compared to the usual chemotherapy drugs given without carboplatin.  The addition of carboplatin to the usual chemotherapy could prevent your cancer from returning, but it could also cause side effects.  This study will allow the researchers to know whether giving carboplatin with the usual chemotherapy is better, the same, or worse than giving the usual chemotherapy.  

  • NRG-CC004
  • NSABP B-51
  • The main purpose of this clinical trial is to study women like you who have cancer cells in the lymph nodes at the time that the breast cancer is diagnosed and have chemotherapy before surgery that clears the cancer cells from the lymph nodes.  This study asks 1) if, after lumpectomy, radiation to the breast and lymph nodes will be better than radiation only to the breast at keeping breast cancer from returning, and 2) if, after mastectomy, radiation to the area where the breast used to be and to the lymph nodes is better than no radiation at keeping breast cancer from returning.

  • NSABP B-55
  • The purpose of this study is to compare the addition of olaparib after the usual care of chemotherapy, surgery, and radiation for your type of breast cancer.  In this study, you will get either olaparib or placebo, a pill that looks like the study drug but contains no medication.    

  • RTOG 1119
  • Lapatinib is a drug that has been approved by the FDA for patients with progressive HER2-positive metastatic breast cancer. However, the combination of brain radiation and lapatinib for the treatment of brain metastases is considered research. The combination is being tested because lapatinib was found to improve the effectiveness of radiation therapy in the laboratory. An early study in patients showed that brain radiation and lapatinib can be combined safely. The purpose of this study is to compare the effects of adding lapatinib to standard whole brain radiation therapy (WBRT) on you and your cancer. The study will try to find out whether WBRT or lapatinib plus WBRT is better at safely improving tumor control.  In this study, you will receive either lapatinib plus WBRT or WBRT alone.

  • SWOG S1207
  • The purpose of this study is to see whether treatment with everolimus plus hormone treatment after chemotherapy will increase the time without your cancer returning.  The current standard treatment after chemotherapy is hormone treatment alone.  Everolimus is a drug currently approved for the treatment of patients with advanced or metastatic kidney or breast cancer.  It is considered research for non-metastatic breast cancer patients.  In this study you will get hormone treatment with either everolimus or with placebo (a pill with no medication). The combination of hormone-treatment and everolimus is research in patients with breast cancer

  • SWOG S1416
  • The main purpose of this study is to compare any good and bad effects of using ABT-888 (Veliparib) (a “PARP” inhibitor) along with cisplatin to using cisplatin alone.  The drug being tested in this study is called ABT-888.  It is investigational, which means it has not been approved for use by the U.S. Food and Drug Administration (FDA). The addition of ABT-888 to cisplatin is an experimental approach. This combination could shrink your cancer but it could also cause side effects. This study will allow researchers to know whether this different approach is better, the same, or worse than the usual approach of chemotherapy. The chemotherapy drug, cisplatin, is used for the treatment of breast cancer although it is not FDA approved for this use. Cisplatin has shown treatment response with tumor shrinkage in patients with metastatic breast cancer, including patients with the triple-negative breast cancer and BRCA mutation-associated breast cancer.

  • SWOG S1418
  • The purpose of this study is to compare the usual approach (i.e. no more treatment or additional post-operative chemotherapy), to any effects, good and/or bad, of the experimental drug MK-3475 (also called pembrolizumab) after surgery.  This study will allow the researchers to know whether treatment with MK-3475 (pembrolizumab) is better, the same, or worse than the usual approach.     

  • WF 97116